Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Spoorenberg, Simone M C ^a   Bos, Willem Jan W ^a   Heijligenberg, Rik ^b   Voorn, Paul G P ^a   Grutters, Jan C ^a,c   Rijkers, Ger T ^a,d   van de Garde, Ewoudt M W ^a,e  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Roosevelt Academy   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bacterial infection; Health economist; Pneumonia; Respiratory infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL DNA; BACTERIAL RNA; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CREATININE; DEXAMETHASONE; GLUCOSE; LINCOSAMIDE; MACROLIDE; PENICILLIN DERIVATIVE; PLACEBO; POTASSIUM; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SODIUM; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UREA;

ADULT; AIRWAY; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BRONCHOSCOPY; CHLAMYDOPHILA; CLINICAL CHEMISTRY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; COXIELLA BURNETII; DISEASE SEVERITY; DRUG COST; FEMALE; GENE AMPLIFICATION; GENERAL WARD NURSING; HAEMOPHILUS INFLUENZAE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOASSAY; IMMUNOPATHOLOGY; INTENSIVE CARE UNIT; LABORATORY TEST; LARYNGOSCOPY; LEGIONELLA PNEUMOPHILA; LEUKOCYTE; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; NURSING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLEURA EMPYEMA; PNEUMONIA SEVERITY INDEX; RADIODIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; SPUTUM EXAMINATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; URINALYSIS;

AGED; AGED, 80 AND OVER; BACTERIA; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA;

EID: 84902301303     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-335     Document Type: Article

References (28)

1. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002, 50(16):1-85.
2. Thomas CP, Ryan M, Chapman JD, Stason WB, Tompkins CP, Suaya JA, Polsky D, Mannino DM, Shepard DS. Incidence and Cost of Pneumonia in Medicare Beneficiaries. Chest 2012, 142(4):973-981. 10.1378/chest.11-1160, 22406959.
3. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005, 294(21):2712-2719. 10.1001/jama.294.21.2712, 16333006.
4. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004, 39(11):1642-1650. 10.1086/425615, 15578365.
5. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, De Zeeuw J, Schultze-Werninghaus G. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005, 128(4):2238-2246. 10.1378/chest.128.4.2238, 16236880.
6. Monge V, San-Martin VM, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health 2001, 11(4):362-364. 10.1093/eurpub/11.4.362, 11766474.
7. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997, 10(7):1530-1534. 10.1183/09031936.97.10071530, 9230242.
8. Martin LG, Freedman VA, Schoeni RF, Andreski PM. Health and functioning among baby boomers approaching 60. J Gerontol B Psychol Sci Soc Sci 2009, 64(3):369-377. 2670250, 19299256.
9. Tessmer A, Welte T, Schmidt-Ott R, Eberle S, Barten G, Suttorp N, Schaberg T, . CAPNETZ study group Influenza vaccination is associated with reduced severity of community-acquired pneumonia. Eur Respir J 2011, 38(1):147-153. 10.1183/09031936.00133510, 21148226, CAPNETZ study group.
10. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, Van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, Bos WJ, Biesma DH. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377(9782):2023-2030. 10.1016/S0140-6736(11)60607-7, 21636122.
11. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, Takei Y, Gabazza EC. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010, 340:c1004. 10.1136/bmj.c1004, 2834887, 20211953.
12. Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine 2009, 27(34):4694-4703. 10.1016/j.vaccine.2009.05.062, 19520197.
13. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58. 10.1503/cmaj.080734, 2612051, 19124790.
14. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422. doi(1):CD000422.
15. Remmelts HH, Spoorenberg SM, Oosterheert JJ, Bos WJ, De Groot MC, Van de Garde EM. The role of vitamin D supplementation in the risk of developing pneumonia: three independent case-control studies. Thorax 2013, 68(11):990-996. 10.1136/thoraxjnl-2013-203623, 23892991.
16. Endeman H, Meijvis SC, Rijkers GT, Van Velzen-Blad H, Van Moorsel CH, Grutters JC, Biesma DH. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 2011, 37(6):1431-1438. 10.1183/09031936.00074410, 20884746.
17. Van Mens SP, Meijvis SC, Endeman H, Van Velzen-Blad H, Biesma DH, Grutters JC, Vlaminckx BJ, Rijkers GT. Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone. Clin Vaccine Immunol 2011, 18(5):796-801. 10.1128/CVI.00007-11, 3122512, 21367978.
18. DBC Onderhoud Price Table V20120329. [http://www.dbconderhoud.nl/index.php?option=com_docman&task=cat_view&gid=725&Itemid=404].
19. Medicine costs Health Care Institute the Netherlands. [http://www.medicijnkosten.nl/].
20. Capelastegui A, Espana PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, De Goicoechea MJ L, Gorordo I, Esteban C, Altube L, Quintana JM, . on behalf of Poblational Study of Pneumonia (PSoP) Group Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012, 12(1):134. 10.1186/1471-2334-12-134, 3462155, 22691449, on behalf of Poblational Study of Pneumonia (PSoP) Group.
21. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008, 133(3):610-617. 10.1378/chest.07-1456, 17989157.
22. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010, 137(3):552-557. 10.1378/chest.09-1547, 3021366, 19880910.
23. Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nuesch E, Pletz MW, Hecht J, Welte T, Bauer TT. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 2012, 39(3):611-618. 10.1183/09031936.00098411, 21965229.
24. Reyes S, Martinez R, Valles JM, Cases E, Menendez R. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008, 31(5):1061-1067. 10.1183/09031936.00083107, 18448502.
25. Bartolome M, Almirall J, Morera J, Pera G, Ortun V, Bassa J, Bolibar I, Balanzo X, Verdaguer A. Maresme Community-Acquired Pneumonia Study Group (GEMPAC): A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J 2004, 23(4):610-616. 10.1183/09031936.04.00076704, 15083763.
26. Ostermann H, Garau J, Medina J, Pascual E, McBride K, Blasi F, . REACH study group Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm Med 2014, 14(1):36-2466. 10.1186/1471-2466-14-36, 3945058, 24593248, REACH study group.
27. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest 2006, 130(3):807-814. 10.1378/chest.130.3.807, 16963679.
28. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics 2004, 22(11):751-757. 10.2165/00019053-200422110-00005, 15250752.